Prescription medicine
Fluocinolone and neomycin Brand names: Neo-Synalar
Fluocinolone and neomycin (Neo-Synalar) is a prescription medicine. FDA's NDC Directory lists it from 1 generic labeler.
- Generic listed
Check it at the source: the fluocinolone and neomycin FDA label on DailyMed (effective March 18, 2026, Eurofarma, Inc.); every fluocinolone and neomycin label on DailyMed.
Highlights of the record
FDA label of March 18, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageNEO-SYNALAR ® cream is indicated for the treatment of corticosteroid-responsive dermatoses with secondary infection.
Forms and strengths
- 3.5 mg/g / 0.25 mg/g
Cream.
On the market
- Generic approvals
- 1 first June 11, 1963; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 1 of which 1 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 13 through July 30, 2026
What is fluocinolone and neomycin used for?
From the label: indications and usageNEO-SYNALAR ® cream is indicated for the treatment of corticosteroid-responsive dermatoses with secondary infection. It has not been demonstrated that this steroid-antibiotic combination provides greater benefit than the steroid component alone after 7 days of treatment (see WARNINGS section).
FDA pharmacologic class: Aminoglycoside Antibacterial and Corticosteroid.
Source: FDA drug label (Neo-Synalar), Eurofarma, Inc., effective March 18, 2026 (SPL set 1141956e-8a4c-4f80-95d1-f15bdb57fdf6), via openFDA; the full label on DailyMed
Is there a generic for fluocinolone and neomycin (Neo-Synalar)?
The FDA approved the first generic fluocinolone and neomycin on June 11, 1963. 1 generic application is approved; 1 of it carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists fluocinolone and neomycin from 1 labeler under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for fluocinolone and neomycin?
The FDA Adverse Event Reporting System holds 13 reports that list fluocinolone and neomycin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 0 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other aminoglycoside antibacterials
- the pharmacologic class, with prices and generics
- Fluocinolone and neomycin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other